Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Total Non-Current Liabilities came in at $4.4 million in Q1 2026, up 91.01% year-on-year from $2.3 million in Q1 2025, and up 12.97% quarter-over-quarter from $3.9 million in Q4 2025.
Oculis Holding AG (OCS) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Oculis Holding AG's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 91.01% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 91.01% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, up 22.05% from the prior year.
- Total Non-Current Liabilities climbed to $4.4 million in Q1 2026 per OCS's latest filing, from $3.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $127.7 million in Q4 2022 and bottomed at $938676.2 in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $2.5 million (2024), against an average of $12.3 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 98.64% in 2023 and jumped 167.65% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $127.7 million in 2022, then tumbled by 98.64% to $1.7 million in 2023, then surged by 80.18% to $3.1 million in 2024, then increased by 26.08% to $3.9 million in 2025, then increased by 12.97% to $4.4 million in 2026.
- Per Business Quant, the three latest OCS Total Non-Current Liabilities figures stand at $4.4 million (Q1 2026), $3.9 million (Q4 2025), and $4.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.45 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 938,676.16 |
| Dec 31, 2022 | 127.71 Mn |
| Dec 31, 2021 | 124.65 Mn |